Sulfonamide inhibitors: a patent review 2013-present

References

• Boztaş M, Çetinkaya Y, Topal M, et al. Synthesis and carbonic anhydrase isoenzymes I, II, IX, and XII inhibitory effects of dimethoxy-bromophenol derivatives incorporating cyclopropane moieties. J Med Chem. 2015;58(2):640–650.
   PubMed Web of Science ®Google Scholar
• Akbaba Y, Akıncıoğlu A, Göçer H, et al. Carbonic anhydrase inhibitory properties of novel sulfonamide derivatives of aminoindanes and aminotetralins. J Enzyme Inhib Med Chem. 2014;29(1):35–42.
   PubMed Web of Science ®Google Scholar
• Gül Hİ, Kucukoglu K, Yamali C, et al. Synthesis of 4-(2-substitutedhydrazinyl) benzenesulfonamides and their carbonic anhydrase inhibitory effects. J Enzyme Inhib Med Chem. 2016;31(4):568–573.
   PubMed Web of Science ®Google Scholar
• Gül Hİ, Tugrak M, Sakagami H, et al. Synthesis and bioactivity studies on new 4-(3-(4-substitutedphenyl)-3a,4-dihydro-3h-indeno[1,2-c]pyrazol-2-yl) benzenesulfonamides. J Enzyme Inhib Med Chem. 2016;31(6):1619–1624.
   PubMed Web of Science ®Google Scholar
• Gokcen T, Gulcin İ, Ozturk T, et al. A class of sulfonamides as carbonic anhydrase inhibitor. J Enzyme Inhib Med Chem. 2016;31(S2):180–188.
   PubMedGoogle Scholar
• Taslimi P, Sujayev A, Mamedova S, et al. Synthesis and bioactivity of several new hetaryl sulfonamides. J Enzyme Inhib Med Chem. 2017;32(1):137–145.
   PubMed Web of Science ®Google Scholar
• Göçer H, Akıncıoglu A, Öztaskın N, et al. Synthesis, antioxidant and antiacetylcholinesterase activities of sulfonamide derivatives of dopamine related compounds. Arch Pharm. 2013;346(11):783–792.
   PubMed Web of Science ®Google Scholar
• Akıncıoglu A, Topal M, Gülçin İ, et al. Novel sulfamides and sulfonamides incorporating tetralin scaffold as carbonic anhydrase and acetylcholine esterase inhibitors. Arch Pharm. 2014;347:68–76.
   PubMed Web of Science ®Google Scholar
• Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta analysis. Leuk Lymphoma. 2016;57:1300–1310.
   PubMed Web of Science ®Google Scholar
• Dahlen T, Edgren G, Lambe M, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016;165:161–166.
   PubMed Web of Science ®Google Scholar
• Haguet H, Douxfils J, Mullier F, et al. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017;16:5–12.
   PubMed Web of Science ®Google Scholar
• Iurlo A, Orsi E, Cattaneo D, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget. 2015;6:33944–33951.
   PubMed Web of Science ®Google Scholar
• Alhawiti N, Burbury KL, Kwa FA, et al. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res. 2016;145:54–64.
   PubMed Web of Science ®Google Scholar
• Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014;99:1197–1203.
   PubMed Web of Science ®Google Scholar
• Teo YL, Ho HK, Chan A. Metabolism related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol. 2015;79:241–253.
   PubMed Web of Science ®Google Scholar
• Zhanghua G Benzoquinazoline tyrosine kinase inhibitor containing halothiophene sulfonamide structure. CN106349231 (A). 2017.
   Google Scholar
• Ghosh AK, Osswald HL, Prato G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J Med Chem. 2016;59(11):5172–5208.
   PubMed Web of Science ®Google Scholar
• Midde NM, Patters BJ, Rao P, et al. Investigational protease inhibitors as antiretroviral therapies. Expert Opin Invest Drugs. 2016;25(10):1189–1200.
   PubMed Web of Science ®Google Scholar
• Dandache S, Coburn CA, Oliveira M, et al. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008;12:2053−2063.
   Google Scholar
• Kenneth RC, Eric DD, Arnold G, et al. Antiviral bisfuran derivative as HIV protease inhibitor and intermediates thereof. EP2570416 (A1). 2013.
   Google Scholar
• Murali K, Yanda QL, Cebotaru V, et al. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca2 in knock-out mouse models of polycystic kidney disease. J Biol Chem. 2017;292(43):17897–17908.
   PubMed Web of Science ®Google Scholar
• Seidel C, Schnekenburger M, Dicato M, et al. Histone deacetylase 6 in health and disease. Epigenomics. 2015;7:103–118.
   PubMed Web of Science ®Google Scholar
• Cebotaru L, Liu Q, Yanda MK, et al. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease. Kidney Int. 2016;90:90–99.
   PubMed Web of Science ®Google Scholar
• Jaekwang L, Younghue H, Yuntae K, et al. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same. AU2016299484 (A1). 2018.
   Google Scholar
• Tonks NK, Diltz CD, Fischer EH. Purification of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem. 1988;263:6722–6730.
   PubMed Web of Science ®Google Scholar
• Nguyen PH, Ji DJ, Han YR, et al. Selaginellin and biflavonoids as protein tyrosine phosphatase 1B inhibitors from Selaginella tamariscina and their glucose uptake stimulatory effects. Bioorg Med Chem. 2015;23:3730–3737.
   PubMed Web of Science ®Google Scholar
• Liu F, Hill DE, Chernoff J. Direct binding of the proline rich region of protein tyrosine phosphatase 1B to the src homology 3 domain of p130Cas. J Biol Chem. 1996;271:31290–31295.
   PubMedGoogle Scholar
• Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283:1544–1548.
   PubMed Web of Science ®Google Scholar
• Frangioni JV, Beahm PH, Shifrin V, et al. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell. 1992;68:545–560.
   PubMed Web of Science ®Google Scholar
• Yongli D, Qunyi L, Jingkang S, et al. Novel sulfonamide compound, preparation method, and use of novel sulfonamide compound as protein tyrosine phosphatase 1B inhibitor. CN106344552 (A). 2017.
   Google Scholar
• Childress ES, Kharel Y, Brown AM, et al. Transforming sphingosine kinase 1 inhibitors into dual and sphingosine kinase 2 selective inhibitors: design, synthesis, and in vivo activity. J Med Chem. 2017;60:3933–3957.
   PubMedGoogle Scholar
• Plano D, Amin S, Sharma AK. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. J Med Chem. 2014;57:5509–5524.
   PubMed Web of Science ®Google Scholar
• Baek DJ, MacRitchie N, Anthony NG, et al. Structure-activity relationships and molecular modeling of sphingosine kinase inhibitors. J Med Chem. 2013;56:9310–9327.
   PubMed Web of Science ®Google Scholar
• Rose PM, Maxwell PS Benzene sulfonamide-based inhibitors of sphingosine kinase. WO2016007993 (A1). 2016.
   Google Scholar
• Conda-Sheridan M, Reddy PVN, Morrell A, et al. Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1). J Med Chem. 2013;56:182–200.
   PubMed Web of Science ®Google Scholar
• Sirivolu VR, Vernekar SK, Marchand C, et al. 5-Arylidenethioxothiazolidinones as inhibitors of tyrosyl-DNA phosphodiesterase I. J Med Chem. 2012;55:8671–8684.
   PubMed Web of Science ®Google Scholar
• Zakharenko AL, Khomenko TM, Zhukova SV, et al. Synthesis and biological evaluation of novel tyrosyl-DNA phosphodiesterase 1 inhibitors with a benzopentathiepine moiety. Bioorg Med Chem. 2015;23:2044–2052.
   PubMed Web of Science ®Google Scholar
• Yves P, Christophe M, Periyasamy S, et al. Fluoroquinolone derivatives or sulfonamide moiety-containing compounds as inhibitors of tyrosyl-dnaphosphodiesterase (TDP1). US8716295 (B2). 2014.
   Google Scholar
• Taslimi P, Akıncıoğlu H, GulçIn i. Synephrine and phenylephrine act as α-amylase, α-glycosidase, acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase enzymes inhibitors. J Biochem Mol Toxicol. 2017;31(11):e21973.
   Web of Science ®Google Scholar
• Scozzafava A, Passaponti M, Supuran CT, et al. Carbonic anhydrase inhibitors: guaiacol and catechol derivatives effectively inhibit certain human carbonic anhydrase isoenzymes (hCA I, II, IX, and XII). J Enzyme Inhib Med Chem. 2015;30(4):586–591.
   PubMed Web of Science ®Google Scholar
• Öztaskın N, Taslimi P, Maras A, et al. Novel antioxidant bromophenols with acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase inhibitory actions. Bioorg Chem. 2017;74:104–114.
   PubMed Web of Science ®Google Scholar
• Gulcin İ, Abbasova M, Taslimi P, et al. Synthesis and biological evaluation of aminomethyl and alkoxymethyl derivatives as carbonic anhydrase, acetylcholinesterase and butyrylcholinesterase inhibitors. J Enzyme Inhib Med Chem. 2017;32(1):1174–1182.
   PubMed Web of Science ®Google Scholar
• Koçyigit UM, Taslimi P, Gezegen H, et al. Evaluation of acetylcholinesterase, and carbonic anhydrase inhibition profiles of 1,2,3,4,6-pentasubstituted-4-hydroxy-cyclohexanes. J Biochem Mol Toxicol. 2017;31(9):e21938.
   Web of Science ®Google Scholar
• Aktas A, Taslimi P, Gülçin i, et al. Novel NHC Precursors: synthesis, characterization and carbonic anhydrase and acetylcholinesterase inhibitory properties. Arch Pharm. 2017;350(6):e1700045.
   Web of Science ®Google Scholar
• Bayrak Ç, Taslimi P, Gülçin İ, et al. The first synthesis of 4-phenylbutenone derivative bromophenols including natural products and their inhibition profiles for carbonic anhydrase, acetylcholinesterase and butyrylcholinesterase enzymes. Bioorg Chem. 2017;72:359–366.
   PubMed Web of Science ®Google Scholar
• Afang Z, Huang S, Runlang Z, et al. Thermosensitive cyclodextrin-based carbonic anhydrase inhibitor and preparation method thereof. CN106822174 (A). 2017.
   Google Scholar
• Aksu K, ÖZgeriş B, Taslimi P, et al. Antioxidant activity, acetylcholinesterase and carbonic anhydrase inhibitory properties of novel ureas derived from phenethylamines. Arch Pharm. 2016;349:944–954.
   PubMed Web of Science ®Google Scholar
• Garibov E, Taslimi P, Sujayev A, et al. Synthesis of 4,5-disubstituted-2-thioxo-1,2,3,4-tetrahydropyrimidines and investigation of their acetylcholinesterase, butyrylcholinesterase, carbonic anhydrase I/II inhibitory and antioxidant activities. J Enzyme Inhib Med Chem. 2016;31(S3):1–9.
   PubMed Web of Science ®Google Scholar
• Özbey F, Taslimi P, Gulcin İ, et al. Synthesis, acetylcholinesterase, butyrilcholinesterase, carbonic anhydrase inhibitory and metal chelating properties of some novel diaryl ether. J Enzyme Inhib Med Chem. 2016;31(S2):79–85.
   PubMedGoogle Scholar
• Pascal B, Sophie C, Philippe D, et al. An H3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of Alzheimer’s disease. CN105764510 (A). 2016.
   Google Scholar
• Rodon J, Dienstmann R, Serra V, et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143–153.
   PubMed Web of Science ®Google Scholar
• William B, Canne BL, David BS, et al. Phosphatidyl inositol 3-kinase inhibitor and application method thereof. JP2015091860 (A). 2015.
   Google Scholar
• Hall RD, Lee TM, Haggstrom DE, et al. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015;4:515–523.
   PubMed Web of Science ®Google Scholar
• Takashi O, Yoichi O, Taro S Use of sulfonamide-including compounds in combination with angiogenesis inhibitors. US8772269 (B2). 2014.
   Google Scholar